Dopavision GmbH is a digital-health startup based in Berlin with the mission to disrupt vision care with digital solutions. We are backed with venture capital and a research grant from the German Federal Ministry of Education and Research (BMBF). We are developing a digital solution for myopia control which aims at modulating retinal dopamine by artificial light, in order to regulate the eyeball growth. We have successfully conducted proof-of-concept experiments and are now moving into pre-clinical investigations together with national and international academic partners. We are a team of 4 experienced scientists and startup entrepreneurs and supported by renowned scientific advisors and strategic pharmaceutical partners.